HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Amgen Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Amgen Intelligence Report

Generated from 14 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 1, 2026

Confidence

Moderate Confidence · 69%

Evidence

77 items

Sources

16

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Amgen maintains an active intelligence profile across Oncology, VEGF Inhibitor, Hematology, Neutropenia, Endocrinology. 14 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 69% across 3 tracked sources. Highest-priority development: FDA AP — NEUPOGEN (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Amgen; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 16, 2026

    FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

    Oncology · NRG1 Fusion-Positive Cholangiocarcinoma · opportunity score 87

    View detail
  2. regulatory

    FDA AP — NEUPOGEN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — REPATHA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — BKEMV (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — PROLIA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Investigational New Drug (IND) Application

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — REPATHA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — BKEMV (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — PROLIA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — NEUPOGEN (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — REPATHA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 1163 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — NEUPOGEN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — REPATHA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BKEMV (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PROLIA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — REPATHA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BKEMV (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PROLIA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NEUPOGEN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — REPATHA (SUPPL)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BKEMV (SUPPL)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PROLIA (SUPPL)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PAVBLU (SUPPL)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA AP — SARCLISA ESCENA (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)

    Oncology · Monoclonal Antibody

  • FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

    Oncology · NRG1 Fusion-Positive Cholangiocarcinoma

  • Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer

    Oncology · Prostate Cancer

  • Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

    Oncology · Pancreatic Adenocarcinoma

  • Amgen's BLA761298 for PAVBLU Receives AP Status from FDA

    Oncology · VEGF Inhibitor

  • Amgen's MARITIME-2-EXTENSION Trial Evaluates Maridebart Cafraglutide for Obesity and Type 2 Diabetes

    Endocrinology · Obesity and Type 2 Diabetes

  • Interfant-21 Study on Blinatumomab for Infants with KMT2A-rearranged ALL

    Oncology · Acute Lymphoblastic Leukemia

  • FDA Accepts Supplement for BLA761333 by Amgen for Eculizumab-AEEB

    Immunology · Complement Inhibition

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.